CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. - Wikidata - awgldk - TriplyDB

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

http://www.wikidata.org/entity/Q34084652

about

Epigenetic therapy in gastrointestinal cancer: the right combination Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review Molecular phenotypes of colorectal cancer and potential clinical applications Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis CpG Island Methylator Phenotype-High Colorectal Cancers and Their Prognostic Implications and Relationships with the Serrated Neoplasia Pathway Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer Epigenetic Biomarkers in Colorectal Cancer.Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system.The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases DNA methylation status of epithelial-mesenchymal transition (EMT)--related genes is associated with severe clinical phenotypes in ulcerative colitis (UC).Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma.Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer.Molecular markers predictive of chemotherapy response in colorectal cancer Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX.Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients.Longitudinal molecular characterization of endoscopic specimens from colorectal lesions.Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon.The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications.Current and future biomarkers in the treatment of colorectal cancer.A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome.DNA methylation aberrancies as a guide for surveillance and treatment of human cancers.Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival.CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.Prognostic significance of CpG island methylator phenotype in colorectal cancer.Colorectal cancer: epigenetic alterations and their clinical implications.DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer.Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism.CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.Meta-analysis of the prognostic value of CpG island methylator phenotype in gastric cancer.CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases.

P2860

Q26745709-59AEC470-F9CD-483B-B8E7-8BB30503BF99 Q26751035-C5C66B6C-DCF7-4DEA-ADF5-DB000DDD0A87 Q26768471-81FDA8CE-1D8B-4F36-9C7D-C178872314CA Q26785725-D8D3E62B-7196-41A2-AE5C-F3EB50FA04B4 Q26787260-CE7C4971-C8C8-4422-B096-43338E1F865B Q28066004-D47C5D25-D763-4F3C-8A25-7903D42B7786 Q28084346-7A880173-64CC-47AD-B0EC-09331572A2F2 Q30240778-92CC3CEC-D1BA-42A2-B810-EC487A54859A Q33577619-0ECAFF76-5FC6-4060-A6FC-414DB85FFE22 Q33630343-B945CF45-D5A0-4FDB-9548-36E8A5F14795 Q34323103-23C9B6A9-5DA1-43D7-93EE-CE161EF870BA Q34487177-F79CB7BB-B890-45A1-88B9-03B32CB7467C Q35066048-59B573E9-2CF6-44E4-9E92-80B57B95AFCD Q35138892-206A2320-36F1-4610-AB53-AE926E22499A Q35761956-3E628559-DB02-407F-9061-87B399486706 Q35831602-3F350B11-4444-4C1F-AAF7-48C6267CAC78 Q36213070-589BA23D-6447-4C63-AA0E-CE515DE1E624 Q36656549-23DE248E-E3B7-4F21-A037-855DB2CC3819 Q36893961-E22E6F66-49E3-43E8-B441-D8CE7E57D37F Q36895084-2C6480CE-CFD3-4D06-BFA9-F597C1265D85 Q36919467-D59A354A-D7ED-4A44-90FF-E990CB573BAF Q37100708-7C2A780B-369E-4150-BDEA-29B3AF9DA373 Q38555225-032145F3-D303-408D-A2E1-F4CF2465AE4C Q38730744-2EA80645-4922-4842-B0DE-ADDE3C488639 Q38785704-AE3C863A-A771-4822-8723-B38DF9614333 Q38787244-7C8907D9-318A-4E54-B947-5676951B14EE Q39028173-01E66014-F8A6-4E71-BDC5-464102BC63C4 Q39208639-D6DED0EE-FCFC-45D9-BDE0-F3698B65A802 Q40603067-53D1AC8A-4E71-47A2-9E8F-182252916091 Q40864425-1E4647C1-6C58-4C2C-9EC6-CC559E5963A5 Q41066289-D406DE3C-D2BC-48C8-9A99-8DBB0FB99601 Q43177934-ED638015-69B6-40AF-8E0C-E8A153154566 Q46112381-7BC4001F-7FC0-495F-8AD9-145B8FDDFA88 Q46181764-973AF290-B9B4-4171-BE0F-D5CBF91D9259 Q47562422-5E235B7C-F71B-4081-9B1B-182765FF1092 Q47870743-D5E752FB-3E98-41CD-B5AD-FFF9ABBF6F97 Q47890522-7C8FAFBE-6C17-4569-BA56-4787DEFBB4EF Q50010486-E3B0EBE0-82D3-41DE-B975-438C214BB582 Q50607666-56BCA2E2-80D9-4817-B361-5885062FEC19 Q55125985-51448513-E6E9-4CA1-8D3D-0C9FC5BAFB61

P2860

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

http://www.wikidata.org/entity/Q34084652

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

CpG island methylator phenotyp ...... py for stage III colon cancer.

@ast

CpG island methylator phenotyp ...... py for stage III colon cancer.

@en

CpG island methylator phenotyp ...... py for stage III colon cancer.

@nl

type

label

CpG island methylator phenotyp ...... py for stage III colon cancer.

@ast

CpG island methylator phenotyp ...... py for stage III colon cancer.

@en

CpG island methylator phenotyp ...... py for stage III colon cancer.

@nl

prefLabel

CpG island methylator phenotyp ...... py for stage III colon cancer.

@ast

CpG island methylator phenotyp ...... py for stage III colon cancer.

@en

CpG island methylator phenotyp ...... py for stage III colon cancer.

@nl

P1433

Q34084652-F7A7568E-94FD-443E-AA9B-0C945B22C15F

P1476

Q34084652-89560C30-8ABC-4668-A5EF-960FD88488EA

P2093

Q34084652-045EFB89-4650-4D74-9C39-FA65CEE1D79E

Q34084652-06DF6364-6F94-45CF-AB3D-6B86D3B4113A

Q34084652-09659B9D-A55C-4FC8-B73B-D9AFA3A20D9F

Q34084652-192759BD-86C8-4632-962D-4921F3A83078

Q34084652-1DD7AA80-8AE4-40A7-BAB9-AEE432C73D2D

Q34084652-248590AC-92BF-4286-844B-8259F0622453

Q34084652-60B202C1-F8EA-43F1-96DE-B81901DCB5B5

Q34084652-63749B9E-AEB3-4929-B732-C39595F92196

Q34084652-A0C6FB92-02AE-4DC1-B61D-1EEC919A9DE0

Q34084652-A9F07422-1AFF-4333-82EF-1A491C4C06F2

P2860

Q34084652-03490323-AF23-4CE8-AD9C-B654E6FFFC93

Q34084652-1F7B7B30-C03B-4242-8CED-3C1BDB4FB374

Q34084652-1F821892-D868-491F-B757-DD06A60B3CB9

Q34084652-20EDA9BB-4989-44FB-86C5-D66E3DE29C66

Q34084652-2DF870C0-4F19-4A1B-9DA6-19DE6E0700B9

Q34084652-30149611-0847-4BA6-99E2-B6859224D82D

Q34084652-33837E04-A9CB-4E23-ABE8-87AE9BE0320B

Q34084652-3617E338-BB05-45C2-B4C8-2C49BC73E075

Q34084652-3CB869F7-400E-4C2A-ACE3-CEBCE516B498

Q34084652-41D345BD-03B9-4853-88BA-26EB8DA85426

P304

Q34084652-A0F4EDEE-EE61-4C3C-AEA8-6611F0C31349

P31

Q34084652-AFA302DB-1108-4654-B4DC-FFC8DEBA6AC3

P356

Q34084652-69677596-D63C-4CCC-B9DF-7A1DFC8BAA83

P407

Q34084652-17AD2EC5-7511-4BE1-AC60-2A2160F790C7

P433

Q34084652-20DF5BF6-6B2A-4D1A-A89F-36A2D610BB7D

P478

Q34084652-5EF5D52B-ADF2-4C12-BA80-770DA5E3196A

P50

Q34084652-51C2E977-2BDF-49B5-B490-8DBAC029BD25

P577

Q34084652-CA102E02-EC97-4759-8AC9-4E87B5DF9CDC

P698

Q34084652-BE1568A3-6A68-4178-A3A1-EBF0F8D9A05A

P932

Q34084652-32C1167C-7478-423B-BBEC-383A2F81344E

P356

J.GASTRO.2014.05.009

P1433

Gastroenterology

P1476

CpG island methylator phenotyp ...... apy for stage III colon cancer

@en

P2093

Alan Venook

http://www.w3.org/2001/XMLSchema#string

Alliance for Clinical Trials in Oncology

http://www.w3.org/2001/XMLSchema#string

Donna Niedzwiecki

http://www.w3.org/2001/XMLSchema#string

Eunmi Nam

http://www.w3.org/2001/XMLSchema#string

Lindsay A Renfro

http://www.w3.org/2001/XMLSchema#string

Mary J Emond

http://www.w3.org/2001/XMLSchema#string

Monica M Bertagnolli

http://www.w3.org/2001/XMLSchema#string

Nancy Maizels

http://www.w3.org/2001/XMLSchema#string

Nathan R Foster

http://www.w3.org/2001/XMLSchema#string

Raymond J Monnat

http://www.w3.org/2001/XMLSchema#string

P2860

CpG island methylator phenotype in colorectal cancer

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803

Systematic review of microsatellite instability and colorectal cancer prognosis

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

Genomic and epigenetic instability in colorectal cancer pathogenesis.

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.

Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803

Colorectal cancer molecular biology moves into clinical practice.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

P304

637-645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2014.05.009

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

147

http://www.w3.org/2001/XMLSchema#string

P50

Leonard B. Saltz

P577

2014-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24859205

http://www.w3.org/2001/XMLSchema#string

P932

4143495

http://www.w3.org/2001/XMLSchema#string